Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Rachana Maniyar"'
Autor:
Taha Merghoub, Sadna Budhu, Roberta Zappasodi, Levi Mangarin, Svena Verma, Inna Serganova, Rachana Maniyar, Ronald Blasberg, Myat Ko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/702856aef21c4cb583270d02123e1591
Autor:
Daniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, Andrew Chow, Levi M.B. Mangarin, Adam D. Cohen, Linda Hamadene, Gabrielle A. Rizzuto, Sadna Budhu, Nathan Suek, Cailian Liu, Alan N. Houghton, Taha Merghoub, Jedd D. Wolchok
Publikováno v:
JCI Insight, Vol 6, Iss 20 (2021)
Only a subset of cancer patients responds to checkpoint blockade inhibition in the clinic. Strategies to overcome resistance are promising areas of investigation. Targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR
Externí odkaz:
https://doaj.org/article/e630bf7834ce472b9967dd8f1a880b48
Autor:
Yasin Senbabaoglu, Greg Delgoffe, Ping-Chih Ho, Arnab Ghosh, Svena Verma, McLane Watson, Inna Serganova, Ivan Cohen, Masatomo Maeda, Masahiro Shindo, Rachana Maniyar, Mayuresh Mane, Avigdor Leftin, Matthew Lubin, Myat Kyaw Ko, Mohsen Abu-Akeel, Ellen Ackerstaff, Jason Koutcher, Ronald Blasberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/b9686a1d31f84b0980888ec7c87b331e
Autor:
Rachana Maniyar, Roberta Zappasodi, Yuval Elhanati, Samantha St Jean, Sebastian Carrasco, Benjamin Greenbaum, Jedd Wolchok, Taha Merghoub
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3afef8e83daa729e150bfd386a8cf43
https://doi.org/10.1136/jitc-2022-sitc2022.0843
https://doi.org/10.1136/jitc-2022-sitc2022.0843
Autor:
Inna Serganova, Jedd D. Wolchok, Levi Mangarin, Taha Merghoub, Sadna Budhu, Myat Ko, Rachana Maniyar, Svena Verma, Ronald G. Blasberg, Roberta Zappasodi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmune checkpoint blockade (ICB) has revolutionized the treatment of many cancer types; however, many patients do not benefit from these therapies due to inherent or acquired resistance. Preferential engagement in glycolysis is a hallmark o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1e1dd3be0ff177552893abe1495ac2
https://doaj.org/article/702856aef21c4cb583270d02123e1591
https://doaj.org/article/702856aef21c4cb583270d02123e1591
Autor:
Ivan J. Cohen, Matthew Lubin, Taha Merghoub, Ping-Chih Ho, Mohsen Abu-Akeel, Arnab Ghosh, Ronald G. Blasberg, Greg M. Delgoffe, Svena Verma, Inna Serganova, Myat Ko, Ellen Ackerstaff, Masatomo Maeda, Avigdor Leftin, Jason A. Koutcher, Masahiro Shindo, Roberta Zappasodi, Yasin Senbabaoglu, McLane Watson, Rachana Maniyar, Jedd D. Wolchok, Mayuresh Mane
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Durable clinical responses to immune checkpoint blockade (ICB) occur in a limited fraction of patients. We thus hypothesized that the characteristic tumor metabolic switch towards aerobic glycolysis could contribute to ICB resistance. High
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2398df6dae99e5e70a50f2426dbbe2d4
https://doaj.org/article/b9686a1d31f84b0980888ec7c87b331e
https://doaj.org/article/b9686a1d31f84b0980888ec7c87b331e
Publikováno v:
Journal of Cancer
Angiogenesis, a highly regulated process, is exploited by tumors like breast cancer to ensure a constant supply of oxygen and nutrients and is key for tumor survival and progression. Estrogen and alcohol independently have been observed to contribute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354888e8bc239bedc05e9b70f4027c14
http://europepmc.org/articles/PMC6218769
http://europepmc.org/articles/PMC6218769
Autor:
Marc K. Wallack, Sanjukta Chakraborty, Tara Jarboe, Rachana Maniyar, Raj K. Tiwari, Jan Geliebter, Anitha Srinivasan, John Degliuomini
Publikováno v:
Cancer Research. 81:1624-1624
Melanoma, the most aggressive form of skin cancer, is still a challenge despite the advent of recent immunotherapies using checkpoint inhibitors. The presence of checkpoint molecules on immune cells serve to regulate optimal immune responses, however
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ef3e565a5eeff9c245f6fcabe427296
https://doi.org/10.1158/1538-7445.am2021-1624
https://doi.org/10.1158/1538-7445.am2021-1624
Autor:
Marc K. Wallack, Robert Bednarczyk, Raj K. Tiwari, Rachana Maniyar, Neha Y. Tuli, Debabrata Banerjee, Marc Wallack Wallack, Sarnath Singh, Jan Geliebter, Ghada Ben Rahoma, Abraham Mittelma
Publikováno v:
International Journal of Translational Science. 2016:33-60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bf73397970e20a0a5c4d428844ae7dd
https://doi.org/10.13052/ijts2246-8765.2016.003
https://doi.org/10.13052/ijts2246-8765.2016.003
Autor:
Avigdor Leftin, Rachana Maniyar, Svena Verma, Inna Serganova, Myat Ko, Jason A. Koutcher, Mayuresh Mane, Taha Merghoub, Masahiro Shindo, Ellen Ackerstaff, Roberta Zappasodi, Yasin Senbabaoglu, Ronald G. Blasberg, Greg M. Delgoffe, Arnab Ghosh, Jedd D. Wolchok, Masatomo Maeda, Ivan J. Cohen, Matthew Lubin, Ping-Chih Ho
Publikováno v:
Cancer Research. 80:3257-3257
Only a limited fraction of patients derives durable clinical benefit upon immune checkpoint blockade. Deepening our understanding of mechanisms of response and resistance to these therapies is thus needed to optimize their employment in rational comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7889f66cb7d0a4c271243ec8b641c2a
https://doi.org/10.1158/1538-7445.am2020-3257
https://doi.org/10.1158/1538-7445.am2020-3257